[-] Show simple item record

dc.contributor.authorSarkissian, Angelaeng
dc.contributor.authorNeher, Jon O.eng
dc.contributor.authorSingh, Ravipaleng
dc.contributor.authorSt. Anna, Leilanieng
dc.date.issued2012eng
dc.description.abstractVenlafaxine reduces hot flashes more than placebo in women with a history of breast cancer; adverse effects include dry mouth and constipation (strength of recommendation [SOR]: B, randomized clinical trials [RCTs] with heterogeneous outcomes). Gabapentin also reduces hot flashes more than placebo (SOR: B, a single RCT); adverse effects include dizziness and somnolence (SOR: C, standard reference). After having tried both medications, women tend to prefer venlafaxine (SOR: C, open-label crossover trial). Treating hot flashes is an off-label use for both drugs.eng
dc.identifier.urihttp://hdl.handle.net/10355/16181eng
dc.languageEnglisheng
dc.publisherFamily Physicians Inquiries Networkeng
dc.relation.ispartofcollectionClinical Inquiries, 2012 (MU)eng
dc.relation.ispartofcommunityUniversity of Missouri-Columbia. School of Medicine. Department of Family and Community Medicine. Family Physicians Inquiries Network.eng
dc.relation.ispartofseriesJournal of family practice, 61, no. 12 (December 2012): 759+.eng
dc.rightsOpenAccess.eng
dc.rights.licenseThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License.eng
dc.subjecthot flasheseng
dc.subjectpreventative treatmenteng
dc.subjectbreast cancereng
dc.subjectGabapentin -- Effectivenesseng
dc.subject.lcshVenlafaxine -- Effectivenesseng
dc.subject.lcshMenopause -- Alternative treatmenteng
dc.subject.lcshBreast -- Cancer -- Patientseng
dc.titleDo venlafaxine and gabapentin control hot flashes in women with a history of breast cancer?eng
dc.typeArticleeng


Files in this item

[PDF]

This item appears in the following Collection(s)

[-] Show simple item record